Singapore-based Juniper Biologics Awarded the Most Innovative Oncology Pharmaceutical Company 2023 by GHP Healthcare and Pharmaceutical Awards
SINGAPORE, Oct. 24, 2023 /PRNewswire/ — Juniper Biologics, a global science-led pharmaceutical company headquartered in Singapore, has been honored with the prestigious title of the “Most Innovative Oncology Pharmaceutical Company 2023” by the Global Health & Pharma (GHP) Healthcare and Pharmaceutical Awards. This recognition underscores Juniper Biologics’ commitment to advancing healthcare by delivering groundbreaking therapies in the field of Oncology and oncology-supportive care.
The annual GHP Awards recognizes healthcare institutions, professionals, and trailblazers for their contributions to the remarkable progress in the healthcare and pharmaceutical fields. The Healthcare and Pharmaceuticals Awards acknowledge those making significant contributions and showcase these outstanding companies and individuals, who, together, improve the world with compassion and care.
Juniper Biologics was founded with a vision to transform the landscape of healthcare by introducing novel therapies designed to address unmet medical needs. The company’s primary areas of focus are Oncology and Oncology Supportive Care, Rare/Orphan Diseases, and Gene Therapy. With an unwavering dedication to improving the lives of patients around the world, Juniper Biologics has garnered acclaim for its innovative approach to pharmaceuticals and its leadership in bringing cutting-edge treatments to market.
The driving force behind Juniper Biologics’ success is its visionary Chief Executive Officer, Raman Singh, a highly experienced healthcare professional with more than two decades of industry knowledge. Under Raman’s guidance, Juniper Biologics has expanded its commercial operations across Asia, Australia, New Zealand, the Middle East, and Africa,
One of the company’s most notable achievements is the successful acquisition of groundbreaking oncology treatments that also feature on the World Health Organization’s (WHO) Essential Medicines List. These treatments have had a profound impact on the lives of individuals battling cancer, underscoring Juniper Biologics’ mission to provide the next generation of life-changing therapies.
Raman Singh, CEO of Juniper Biologics, expressed his appreciation for the company’s recognition as the Most Innovative Oncology Pharmaceutical Company 2023 by GHP. He stated, “This award is a testament to the dedication and passion of the entire Juniper Biologics team. We are committed to pushing the boundaries and creating access to therapies that make a real difference in the lives of patients. Our focus on oncology and oncology-supportive care is aimed at meeting critical unmet needs and providing improved outcomes to patients.
Juniper Biologics remains dedicated to its vision of advancing healthcare and will continue to lead the way in commercializing innovative treatments that improve the quality of patients everywhere.”
About Juniper Biologics
Backed by The Sylvan Group, Juniper Biologics is a science-led healthcare company focused on delivering novel therapies to improve the health and quality of life of patients, by building a growing presence in Oncology and Oncology Supportive Care, Rare/Orphan Diseases, and Gene Therapy. It was founded on a vision to provide treatments for unmet medical needs focused on specialist therapy areas in which it can make the most difference. Through bold and transformative science, Juniper Biologics is committed to creating possibilities that have the potential to become the next generation of life-changing medicines for patient communities in China, Japan, Asia, Australia, New Zealand, the Middle East, and Africa.
Website: https://www.juniperbiologics.com/
LinkedIn: https://www.linkedin.com/company/juniper-biologics
View original content:https://www.prnewswire.co.uk/news-releases/singapore-based-juniper-biologics-awarded-the-most-innovative-oncology-pharmaceutical-company-2023-by-ghp-healthcare-and-pharmaceutical-awards-301964732.html
